614 related articles for article (PubMed ID: 27402157)
21. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
23. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
[TBL] [Abstract][Full Text] [Related]
24. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
Ji T; Chen X; Yeleswaram S
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):894-905. PubMed ID: 35506332
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Landry I; Aluri J; Nakai K; Hall N; Miyajima Y; Ueno T; Dayal S; Filippov G; Lalovic B; Moline M; Reyderman L
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):681-690. PubMed ID: 33455055
[TBL] [Abstract][Full Text] [Related]
27. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
28. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
Britz H; Hanke N; Volz AK; Spigset O; Schwab M; Eissing T; Wendl T; Frechen S; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):296-307. PubMed ID: 30762305
[TBL] [Abstract][Full Text] [Related]
29. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
Mulford DJ; Ramsden D; Zhang L; Michon I; Leifke E; Smith N; Jones HM; Scarpignato C
CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):532-544. PubMed ID: 36896795
[TBL] [Abstract][Full Text] [Related]
30. Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors.
Ueno T; Miyajima Y; Landry I; Lalovic B; Schuck E
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):455-466. PubMed ID: 33704920
[TBL] [Abstract][Full Text] [Related]
31. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
32. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R
Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895
[TBL] [Abstract][Full Text] [Related]
33. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
34. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
35. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Posada MM; Morse BL; Turner PK; Kulanthaivel P; Hall SD; Dickinson GL
J Clin Pharmacol; 2020 Jul; 60(7):915-930. PubMed ID: 32080863
[TBL] [Abstract][Full Text] [Related]
36. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
Chen Y; Ma F; Lu T; Budha N; Jin JY; Kenny JR; Wong H; Hop CE; Mao J
Clin Pharmacokinet; 2016 Jun; 55(6):735-49. PubMed ID: 26692192
[TBL] [Abstract][Full Text] [Related]
37. Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics.
Watanabe A; Kotsuma M
Drug Metab Pharmacokinet; 2024 Apr; 55():101000. PubMed ID: 38458122
[TBL] [Abstract][Full Text] [Related]
38. Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.
Molenaar-Kuijsten L; Braal CL; Groenland SL; de Vries N; Rosing H; Beijnen JH; Koolen SLW; Vulink AJE; van Dongen MGJ; Mathijssen RHJ; Huitema ADR; Steeghs N;
Clin Pharmacol Ther; 2022 Feb; 111(2):477-484. PubMed ID: 34674222
[TBL] [Abstract][Full Text] [Related]
39. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
Samant TS; Huth F; Umehara K; Schiller H; Dhuria SV; Elmeliegy M; Miller M; Chakraborty A; Heimbach T; He H; Ji Y
Clin Pharmacol Ther; 2020 Sep; 108(3):575-585. PubMed ID: 32557601
[TBL] [Abstract][Full Text] [Related]
40. A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.
Kumagai Y; Fujita T; Maeda M; Sasaki Y; Nagaoka M; Huang J; Takenaka T; Kawai M
J Clin Pharmacol; 2020 Jun; 60(6):702-710. PubMed ID: 32026490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
